This article is a conference summary published in Liver International (2026 Sep;46[9]:e70806; doi:10.1111/liv.70806). It reports the key topics and emerging paradigms presented at the First Annual Paris International Liver Meeting 2026, synthesizing expert discussion across multiple hepatology subfields. The PubMed entry links to publisher full-text options (Wiley) and to a free PMC full text.
The summary is authored by a large international group of hepatology experts. Lead and contributing authors represent academic liver centres, hepatology units, and research groups across Europe, North America and Asia. Affiliations listed on the PubMed page include university hospitals, specialised liver centres and global liver research councils. The author list reflects broad multidisciplinary participation including clinical hepatology, hepatobiliary oncology, gastroenterology and liver outcomes research.
The article is presented as an overview of the Paris meeting rather than as a primary research report. Its stated purpose is to summarise emerging paradigms discussed at the meeting across multiple domains of liver disease. The PubMed excerpt available on the summary page does not reproduce detailed session-level data, specific study outcomes, or granular recommendations; those are available in the full-text article referenced on the PubMed page.
The meeting summary identifies MASLD as a major focus area. As presented in the PubMed record, MASLD was one of the thematic pillars of the Paris meeting and was discussed in the context of evolving diagnostic and management approaches. The PubMed page does not include specific trial results, numerical findings, or explicit practice-change recommendations in the abstract excerpt; readers should consult the full text for session-level detail and evidence cited by the presenters.
Viral Hepatitis (acute and chronic viral liver disease) is identified as a principal topic addressed during the meeting. The summary on PubMed notes that viral hepatitis featured among the emerging-paradigm discussions, but the excerpt does not list particular therapeutic advances, eradication strategies, or outcome data. The full text linked from the PubMed entry should be consulted for specific studies, guideline updates, or treatment data reported at the meeting.
Cholestatic Liver Disease was another thematic area covered at the Paris meeting. The PubMed abstract-level content confirms coverage of cholestatic disorders but does not provide the meeting’s specific clinical or mechanistic takeaways in the excerpt. For detailed descriptions of updates in diagnosis, biomarkers, or therapeutic options discussed at the meeting, refer to the full-text summary.
Portal Hypertension was included among the core topics of the meeting summary. The PubMed page indicates this subject was discussed within the broader context of complications of chronic liver disease and management paradigms. The abstract snippet does not contain detailed data, procedural innovations, or guideline changes; the comprehensive account is available in the linked full text.
Hepatocellular Carcinoma (HCC) featured as a primary focus at the Paris meeting and is listed in the article title. The PubMed record shows HCC was addressed alongside other hepatology domains, including hepatobiliary oncology contributors among the authors. Specific trial findings, translational advances, or recommended clinical approaches from the meeting are not reproduced in the PubMed excerpt and require review of the full article for complete information.
The PubMed entry functions as a bibliographic record and provides the title, authors, journal citation and links to the full text. The abstract-level content visible on the PubMed page does not include granular meeting data, numeric results, or detailed recommendations. The PubMed page links to the publisher's full-text options and to a free PMC article (Free PMC article) where the full conference summary and its detailed content can be retrieved. Clinicians and researchers seeking specific study data, session summaries or referenced evidence should consult the full-text article on Wiley or PMC.
The First Annual Paris International Liver Meeting 2026 brought together a broad international panel to discuss evolving paradigms in MASLD, Viral Hepatitis, Cholestatic Liver Disease, Portal Hypertension, and Hepatocellular Carcinoma. The PubMed bibliographic record confirms the meeting’s scope and the multidisciplinary author group, but does not convey the meeting’s detailed content in the abstract snippet. For clinical application, guideline development or citation, refer to the linked full text (Wiley/PMC) for the complete meeting summary, session-level findings and any cited evidence or recommendations.